Meeting News

Meeting News

On location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...
On location

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated acute myeloid leukemia (AML), according to findings from the...
On location

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...

Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma

Adding the antibiotic clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with multiple myeloma (MM), compared with lenalidomide and dexamethasone (Rd)...

DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma

In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of dexamethasone, cisplatin, gemcitabine, and pegasparaginase (DDGP) improved survival compared...

Zanubrutinib Active in Patients with Treatment-Naive Del17p CLL/SLL

Approximately 93% of patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and del17p responded to treatment with the next-generation Bruton tyrosine kinase (BTK)...
On location

How Do Patient and Physician Attitudes Drive Choices in Antiplatelet Therapy for Thrombocytopenia?

Patients with a hematologic malignancy and thrombocytopenia typically are treated with antiplatelet drugs, but there is little information to help clinicians balance the potential...

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Older patients (≥60 years of age) with acute myeloid leukemia (AML) often have lower remission rates and increased induction mortality with intensive induction chemotherapy,...

Durable Response Observed With Pracinostat and Azacitidine for Older Patients With AML

The inhibition of both histone deacetylation (HDAC) and DNA hypermethylation induces re-expression of silenced genes in vitro in cell lines and in primary cells...

More Mutations, More Problems? Assessing Mutation Burden and Response to HMAs in MDS

Previous research has suggested that the presence of a TET2 mutation can predict which patients with myelodysplastic syndromes (MDS) are more likely to have...
Advertisement

Current Issue

February 2020, Volume 6, Issue 3

This issue examines the high price of treating hemophilia, asks whether CAR T-cell therapies are worth the cost, and more.